These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 6151343)

  • 41. Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension.
    Larsson R; Karlberg BE; Norlander B; Wirsén A
    Clin Pharmacol Ther; 1981 May; 29(5):588-93. PubMed ID: 6111409
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of carvedilol in the management of portal hypertension.
    Tripathi D; Hayes PC
    Eur J Gastroenterol Hepatol; 2010 Aug; 22(8):905-11. PubMed ID: 20093937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antihypertensive mechanism of beta-adrenoceptor antagonism--the role of beta 2-blockade.
    Dahlöf B; Andrén L; Svensson A; Hansson L
    J Hypertens Suppl; 1983 Dec; 1(2):112-5. PubMed ID: 6152739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Features of the acute hypotensive action of carvedilol and its ameliorating effect on myocardial ischemia.
    Hashimoto H; Kanda A; Hubo H; Tanaka M
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S22-8. PubMed ID: 1721975
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Carvedilol and the kidney.
    Dupont AG
    Clin Investig; 1992; 70 Suppl 1():S127-31. PubMed ID: 1350479
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties.
    Sponer G; Bartsch W; Strein K; Müller-Beckmann B; Böhm E
    J Cardiovasc Pharmacol; 1987 Mar; 9(3):317-27. PubMed ID: 2437399
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term hemodynamic effects of antihypertensive treatment.
    Lund-Johansen P; Omvik P; Nordrehaug JE
    Clin Investig; 1992; 70 Suppl 1():S58-64. PubMed ID: 1350486
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Studies on the mechanism of the acute antihypertensive and vasodilator actions of several beta-adrenoceptor antagonists.
    Sybertz EJ; Baum T; Pula KK; Nelson S; Eynon E; Sabin C
    J Cardiovasc Pharmacol; 1982; 4(5):749-58. PubMed ID: 6182405
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vasodilatory action of carvedilol.
    Sponer G; Strein K; Bartsch W; Müller-Beckmann B
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S5-11. PubMed ID: 1378150
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension.
    Maggi E; Marchesi E; Covini D; Negro C; Perani G; Bellomo G
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):532-8. PubMed ID: 8847870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Haemodynamic effects of noise exposure before and after beta 1-selective and non-selective beta-adrenoceptor blockade in patients with essential hypertension.
    Andrén L; Hansson L; Björkman M
    Clin Sci (Lond); 1981 Dec; 61 Suppl 7():89s-91s. PubMed ID: 6274580
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hemodynamic profile of carvedilol.
    Hombach V; Kochs M; Höher M; Eggeling T; Haerer W; Wieshammer S; Schmidt A
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S101-3. PubMed ID: 1974496
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of carvedilol on atrial natriuretic peptide, catecholamines, and hemodynamics in hypertension at rest and during exercise.
    Omvik P; Lund-Johansen P; Myking O
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S90-6. PubMed ID: 1378157
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Acute hemodynamic effects of the vasodilator beta blocker carvedilol in heart failure].
    Buchwald A; Unterberg C; van der Does R; Wiegand V
    Z Kardiol; 1990 Jun; 79(6):424-8. PubMed ID: 1974100
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute effects of prizidilol on blood pressure, heart rate, catecholamines, renin and aldosterone in essential hypertension.
    Bianchetti MG; Boehringer K; Weidmann P; Link L; Schiffl H; Ziegler WH
    Eur J Clin Pharmacol; 1982 Oct; 23(4):289-96. PubMed ID: 6129141
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Balanced beta--alpha-blocker treatment with carvedilol in mild-moderate arterial hypertension].
    Perocchio M; Gigli G; Barra M; Sacchetti R; Vallebona A; Rosolen GA; Orlandi S
    Minerva Cardioangiol; 1996 Mar; 44(3):115-21. PubMed ID: 8767610
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preclinical and clinical pharmacology of carvedilol.
    Ruffolo RR; Boyle DA; Venuti RP; Lukas MA
    J Hum Hypertens; 1993 Feb; 7 Suppl 1():S2-15. PubMed ID: 8487245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.
    Omvik P; Lund-Johansen P
    Cardiovasc Drugs Ther; 1993 Apr; 7(2):193-206. PubMed ID: 8395198
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients.
    van den Meiracker AH; Man in't Veld AJ; Boomsma F; Fischberg DJ; Molinoff PB; Schalekamp MA
    Circulation; 1989 Oct; 80(4):903-14. PubMed ID: 2571431
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical pharmacology of multiple action compounds.
    Prichard BN; Tomlinson B
    Z Kardiol; 1989; 78 Suppl 3():1-6. PubMed ID: 2573211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.